Edwards Lifesciences EW Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Europe | $442.6M+29.5% | $409.6M+19.2% | $387.9M+21.3% | $378.2M+13.8% | $341.8M+4.8% | |
| Japan | $90.6M+10.8% | $87.5M+1.9% | $90.1M+10.7% | $95.3M+10.2% | $81.8M-4.9% | |
| Rest of World | $177.8M+18.4% | $165.5M+15.5% | $167.6M+12.8% | $169M+17.1% | $150.2M+10.6% | |
| United States | $937.6M+11.8% | $907M+11.6% | $907.5M+12.8% | $889.7M+10.3% | $838.9M+7.3% | |
| Total other segment items by Business | ||||||
| Europe | $41.9M+605% | $30.4M+485% | $28.9M+502% | $15.2M+1,800% | -$8.3M-302% | |
| Japan | -$6M-30.4% | -$4.3M-187% | -$900K+62.5% | -$200K+94.4% | -$4.6M-757% | |
| Rest of World | -$7.5M+18.5% | -$4.6M-24.3% | -$4.7M-74.1% | -$7.9M-163% | -$9.2M-736% | |
| United States | $800K+33.3% | $600K+50.0% | $700K+16.7% | $600K-14.3% | $600K-14.3% | |
| Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest by Business | ||||||
| Europe | $235.3M+21.0% | $191.1M+3.4% | $206.6M+16.5% | $204M+9.6% | $194.5M+9.9% | |
| Japan | $66.4M+15.1% | $52.9M-1.3% | $59.8M+9.9% | $63.4M+9.5% | $57.7M+21.5% | |
| Rest of World | $89.7M+15.7% | $54.3M-6.9% | $82M+22.0% | $84.7M+40.2% | $77.5M+35.7% | |
| United States | $610.7M+9.2% | $600.5M+11.2% | $599.5M+8.8% | $585.9M+8.2% | $559.1M+6.2% | |
| Selling, general, and administrative expenses by Business | ||||||
| Europe | $71.8M-2.2% | $97.4M+29.3% | $70M+7.7% | $74.2M+4.7% | $73.4M+2.8% | |
| Japan | $15.9M-3.0% | $25.7M+17.9% | $17.9M+1.1% | $18.5M-5.6% | $16.4M-36.9% | |
| Rest of World | $48M+14.0% | $69.7M+38.6% | $49.5M+14.8% | $48.3M+3.6% | $42.1M+1.7% | |
| United States | $154.1M+15.7% | $166.2M+19.7% | $140.2M+11.1% | $135.7M+15.2% | $133.2M+15.6% | |
| Cost of Sales by Business | ||||||
| Europe | $93.6M+13.9% | $90.7M+15.7% | $82.4M+13.3% | $84.8M+14.0% | $82.2M+11.7% | |
| Japan | $14.3M+16.3% | $13.2M+10.0% | $13.3M+13.7% | $13.6M+7.9% | $12.3M+4.2% | |
| Rest of World | $47.6M+19.6% | $46.1M+20.1% | $40.8M-0.5% | $43.9M+8.9% | $39.8M+3.6% | |
| United States | $172M+17.8% | $139.7M+4.3% | $167.1M+32.0% | $167.5M+14.4% | $146M+4.5% | |
| Net Sales by Product | ||||||
| Surgical | $276.2M+10.1% | —— | —— | —— | $250.9M— | |
| Transcatheter Aortic Valve Replacement | $1.2B+14.4% | $1.16B+12.0% | $1.15B+12.4% | $1.13B+8.9% | $1.05B+3.8% | |
| Transcatheter Mitral and Tricuspid Therapies | $175.1M+52.0% | $155.7M+48.1% | $145.2M+59.4% | $134.5M+62.0% | $115.2M+58.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Edwards Lifesciences break its business down?
- Edwards Lifesciences (EW) reports net sales by business across 4 parts — Europe, Japan, Rest of World and United States. Each is extracted from the segment footnotes and tracked over time.
- Where does Edwards Lifesciences's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Edwards Lifesciences's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
